Life Science News

Cloud DX (TSXV:CDX), a leading Canadian provider of virtual care and remote patient monitoring solutions, announced today it has been issued a new US patent for its upcoming Pulsewave 2.0 Vital Sign Monitor

US Patent 11,006,843 entitled ‘System And Method Of Determining Breathing Rates From Oscillometric Data,' protects Cloud DX's innovative method for determining the breathing rate of a patient using an oscillometric device as the physiological sensor. It positions Pulsewave 2.0 as the first home-based vital signs monitor of its kind to simultaneously capture diagnostic-quality blood pressure, heart rate, heartbeat irregularities and respiration rate.

How Pulsewave 2.0 breathing rate technology works

  • Cloud DX's Pulsewave vital signs monitor is worn on a patient's wrist, and oscillometric pulse waveforms are obtained as the cuff deflates, obtaining pulse wave signals and artifact signals over multiple patient breaths.
  • Pulsewave software analyzes these signals producing an envelope of pulse waveforms as well as a frequency modulated sequence of pulses at various time intervals containing breathing rate data.
  • Pulsewave 2.0 operates autonomously but can also be connected to the internet. When connected, clinicians receiving the data can derive additional biological metrics via the Cloud Diagnostics® online platform.

Pulsewave 2.0 is the latest innovation to emerge from Cloud DX's award-winning research and development efforts. It builds and expands on a near decade of experience deploying the original Pulsewave 1.0 wrist cuff blood pressure device. As the world's first cloud-based portable blood pressure device, Pulsewave 1.0 has gathered millions of pulse wave signals from tens of thousands of individuals. Pulsewave's accuracy and precision was validated in a real-world setting in an independent peer-reviewed study published by University of New Brunswick and the New Brunswick Heart Centre, where researchers determined that the Cloud DX device was similar in accuracy to an intra-arterial catheter for blood pressure. (1)

Pulsewave 2.0 is now in clinical trials at Dalhousie Medicine New Brunswick. The Pulsewave program is supported by the NextGen Manufacturing Supercluster and the New Brunswick Health Research Foundation. Pulsewave® and the Cloud Diagnostics® platform are protected by multiple US and international patents.

"Home-based diagnostics are the next frontier of virtual care. Healthcare providers and patients are now seeing first hand the limitations of telehealth and are pressing for a more all-encompassing model of care where telemedicine, home-based patient vitals monitoring and in-person doctor visits work seamlessly together to inform medical diagnosis and treatment. The ability to capture patient vitals - including an accurate respiration rate - in an ongoing, comprehensive way and to have that data flow directly from the patient's body to the care team, will greatly speed accurate clinical decision making, contribute to better patient outcomes, and make care more efficient and more economic for providers and payers," says Robert Kaul, CEO of Cloud DX.

1. A Comparison and Calibration of a Wrist-Worn Blood Pressure Monitor for Patient Management: Assessing the Reliability of Innovative Blood Pressure Devices. JMIR April 2018

Cloud DX

Accelerating virtual healthcare's future, Cloud DX is making healthcare better for everyone. The company's Connected Health remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable ageing in place and deliver hospital-quality post-surgical care. Providers partnering with Cloud DX achieve better healthcare and patient outcomes, reduce the need for hospitalization/re-hospitalization and reduce the costs of healthcare delivery through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist and one of Canada's 10 most prominent Telehealth providers.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

# # #

Social Links


For media inquiries please contact:
Ellyn Winters-Robinson
Ignition Communications (PR for Cloud DX)

For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations

SOURCE:Cloud DX Inc.

View source version on

News Provided by ACCESSWIRE via QuoteMedia

BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty member. The project aims to discover new targets that may lead to the development of novel anti-cancer treatments.

The research collaboration will focus on the discovery and development of novel targets to enhance tumor cell responsiveness to chemotherapy and immunotherapies in specific cancers including lung, head and neck, cervical, and bladder cancers. The research team at Harvard Medical School is led by Joan S. Brugge, PhD, who is the Louise Foote Pfeiffer Professor of Cell Biology and Co-Director of the Ludwig Cancer Center.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event July 7, 2022, at 2:00 PM ET

BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event July 7, 2022, at 2:00 PM ET

 BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") invites its shareholders and the general public to join a Live Video Conference ("Webinar") on Thursday, July 7, 2022, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).

BioHarvest Sciences CEO Ilan Sobel will host the event, which will include coverage of Q2 sales results and a detailed progress update on the 2022 Growth Priorities, with specific focus on the VINIA scale-up progress in the USA and on the Company's Cannabis market entry strategy into North America.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Nanalysis Announces Results of AGM and Appointment of New Director

Nanalysis Scientific Corp. ("the Company", ("the Company", TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ) a leader in portable NMR machines and MRI technology for healthcare and industrial applications, is pleased to report that all proposed resolutions were approved at the Company's Annual General and Special Meeting of shareholders held on June 22, 2022 (the "Meeting"). The number of directors was set at 7 and all director nominees, as listed in the Management Information Circular dated May 20, 2022 (the "Information Circular"), were elected as directors of the Company at the Meeting to serve for a one-year term and hold office until the next annual meeting of shareholders. According to the proxy votes received from shareholders, the results were as follows:

Nanalysis Scientific Corp. (CNW Group/Nanalysis Scientific Corp.)


% For

% Withheld

Sean Krakiwsky

96.566 %

3.434 %

Martin Burian

95.592 %

4.408 %

Werner Gartner

99.852 %

0.148 %

Michal Okoniewski

99.852 %

0.148 %

Guido Cloetens

95.628 %

4.372 %

Rene Lenggenhager

99.852 %

0.148 %

Kham Lin

99.609 %

0.391 %

Shareholders voted 99.85% in favor of setting the number of directors at seven, 99.6% in favor of appointing Ernst & Young LLP, as auditor of the Company for the ensuing year and to authorize the Directors of the Company to fix the auditor's remuneration and 98.1% in favor for the approval of an amended stock option plan of the Company.

Corporate Update

The Company is pleased to welcome Kham Lin to Nanalysis's Board of Directors with immediate effect following shareholder approval at the Meeting.

Mr. Lin is currently a Managing Director at Nanalysis and was formerly the President and Chief Executive Officer of KPrime Technologies before the Company's acquisition by Nanalysis.  Over twenty plus years, Mr. Lin built KPrime, into a manufacturing representative business for global companies like Agilent Technologies, Metrohm USA , Sartorius LPS Division, and Leidos.  KPrime has a portfolio of sales and services in scientific detection and measuring equipment, financing, and asset management for chemical and security industries.  Mr. Lin resides and works in Calgary, Alberta, Canada but also splits time in Phoenix, Arizona at KPrime Headquarters.

About Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA:1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC and the Frankfurt exchange under the ticker symbol '1N1'. The company's business is what we term "MRI and NMR for industry". The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The company has followed-up that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis recently announced that it has begun selling a 100MHz device in 2020. The Company's new device will be the most powerful and most advanced compact NMR device ever brought to market.

Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.

With the recent acquisition of K'Prime, the company maintains a North American sales and service company of over 40 individuals who cover scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems for security applications.

Additionally, the Company has a 43% ownership in Quad Systems AG ("Quad Systems"), with an option to purchase the remaining shares.  Quad Systems is a Zurich-based Nuclear Magnetic Resonance (NMR) company focused on high-field NMR for pharmaceutical and other vertical markets.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia:

SOURCE Nanalysis Scientific Corp.

Cision View original content to download multimedia:

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Applied UV Continues Cannabis Market Expansion

Applied UV Continues Cannabis Market Expansion

Tru Infusion Places Significant Order

Largest Indoor Cannabis Cultivator in Arizona

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Greenlane Renewables Announces Results From 2022 Annual General Meeting of Shareholders

Greenlane Renewables Announces Results From 2022 Annual General Meeting of Shareholders

~All nominated directors and proposed resolutions approved by shareholders~

 Greenlane Renewables Inc. ("Greenlane") (TSX: GRN) (FSE: 52G) is pleased to announce the results from its 2022 Annual General Meeting of Shareholders held on June 22, 2022 (the "Meeting"). Shareholders approved all matters submitted to them for approval at the annual general meeting. The results of the voting are set forth below:

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Applied UV Receives Substantial Order from European Distributor

Applied UV Receives Substantial Order from European Distributor

Cellarius is One of Europe's Fastest Growing Companies

Expanding Airocide's Global Winery Market share

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News